Displaying 1 - 1 of 1
| Active Ingredient | FLUDARABINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL) or after first line treatment in patients with sufficient bone-marrow reserves. |
| Caution | Fludarabine has a potent immunosuppresive effect. Patients treated with fludarabine are more prone to serious bacterial, opportunistic fungal, and viral infections, and prophylactic therapy can be use More ... |
| Dose Range |
40 mg/m2 for 5 days every 28 days, usually given for 6 cycles. By intravenous injection, or by intravenous infusion. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |